Determinants of Calcium Infusion Rate During Continuous Veno-venous Hemofiltration with Regional Citrate Anticoagulation in Critically Ⅲ Patients with Acute Kidney Injury
- Author:
- No author available
- Journal Title:
- Chinese Medical Journal
- Issue:
- 14
- DOI:
- 10.4103/0366-6999.185861
- Key Word:
- Anticoagulation;Calcium;Citrate;Hemofiltration
Abstract： Background:It is unclear that how to decide the calcium infusion rate during continuous veno-venous hemofiltration (CVVH) with regional citrate anticoagulation (RCA).This study aimed to assess the determinants of calcium infusion rate during CVVH with RCA in critically ill patients with acute kidney injury (AKI).Methods:A total of 18 patients with AKI requiring CVVH were prospectively analyzed.Postdilution CVVH was performed with a fixed blood flow rate of 150 ml/min and a replacement fluid flow rate of 2000 ml/h for each new circuit.The infusion of 4％ trisodium citrate was started at a rate of 29.9 mmol/h prefilter and adjusted according to postfilter ionized calcium.The infusion of 10％ calcium gluconate was initiated at a rate of 5.5 mmol/h and adjusted according to systemic ionized calcium.The infusion rate oftrisodium citrate and calcium gluconate as well as ultrafiltrate flow rate were recorded at 1,2,4,6,12,and 24 h after starting CVVH,respectively.The calcium loss rate by CVVH was also calculated.Results:Fifty-seven sessions of CVVH were performed in 18 AKI patients.The citrate infusion rate,calcium loss rate by CVVH,and calcium infusion rate were 31.30 (interquartile range:2.70),4.60 ± 0.48,and 5.50 ± 0.35 mmol/h,respectively.The calcium infusion rate was significantly higher than that of calcium loss rate by CVVH (P ＜ 0.01).The correlation coefficient between the calcium and citrate infusion rates,and calcium infusion and calcium loss rates by CVVH was-0.031 (P ＞ 0.05) and 0.932 (P ＜ 0.01),respectively.In addition,calcium infusion rate (mmol/h) =1.77 + 0.8 × (calcium loss rate by CVVH,mmol/h).Conclusions:The calcium infusion rate correlates significantly with the calcium loss rate by CVVH but not with the citrate infusion rate in a fixed blood flow rate during CVVH with RCA.
- [1]Lips P.Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications.[J].2001,22(4).
- [2]Fall P,Szerlip HM.Continuous renal replacement therapy: cause and treatment of electrolyte complications.[J].2010,23(6).
- [3]Morgera S,Zuckermann Becker H,Peters H,etc.A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status.[J].2009,37(6).
- [4]Louise, Schilder,S Azam, Nurmohamed,Frank H, Bosch,etc.Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial.[J].2014,18.
- [5]Gattas, David J.,Rajbhandari, Dorrilyn,Bradford, Celia,etc.A Randomized Controlled Trial of Regional Citrate Versus Regional Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Adults[J].2015,43(8).
- [6]Chadha V,Garg U,Warady BA,etc.Citrate clearance in children receiving continuous venovenous renal replacement therapy.[J].2002,17(10).
- [7]Godinez Luna T.Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system.[J].2005,20(2).
- [8]Bakker AJ,Boerma EC,Keidel H,etc.Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous haemofiltration: use of ionised and total/ionised calcium.[J].2006,44(8).
- [9]Pasko D,Starmann B,Swartz R,etc.Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation.[J].2004,61(2).
- [10].Regional citrate anticoagulation in critically ill patients with liver and kidney failure[J].2011.
- [11]J.-L.Vincent,R.Moreno,J.Takala,etc.The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure[J].1996,22(7).
- [12]S J, Marx.Hyperparathyroid and hypoparathyroid disorders.[J].2000,343(25).
- [13]Bai, Ming,Zhou, Meilan,He, Lijie,etc.Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs[J].2015,41(12).
- [14]Theodore E, Warkentin,Andreas, Greinacher.Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.[J].2004,126.
- [15]Louise, Schilder,S Azam, Nurmohamed,Pieter M, ter Wee,etc.Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients.[J].2014,15.